Galectin-3 expression is associated with bladder cancer progression and clinical outcome

Galectin-3 belongs to a family of carbohydrate-binding proteins whose function is not fully characterized. However, it is believed to play a role in adhesion, proliferation and apoptosis in solid tumors. We aimed at investigating galectin-3 expression in bladder cancer. Galectin-3 expression was assessed by transcript profiling (U133A arrays) in a series or frozen bladder tumors (n = 105). Immunohistochemistry was performed on tissue arrays containing bladder tumors (n = 389) to evaluate associations of protein expression patterns of galectin-3 with proliferation (Ki67), apoptosis (apopdetek), bcl-2, and clinicopathologic variables. Galectin-3 protein levels were then quantified in 160 urinary specimens of bladder cancer patients and controls by enzymeimmunoanalysis. Galectin-3 gene expression levels increased in invasive tumours as compared with non-muscle invasive lesions (p = 0.001) and were associated with poor survival in patients with advanced disease (p = 0.03). Protein expression patterns also correlated galectin-3 with tumor stage (p < 0.001), grade (p = 0.03), Ki67 and apopdetek (p < 0.001), and overall survival in patients with T1G3 tumors (p < 0.001). Furthermore, galectin-3 urinary levels segregated bladder cancer patients from controls with high diagnostic accuracy (AUC = 0.7). Independent series of bladder tumors showed that transcript and protein levels of galectin-3 were differentially expressed along bladder cancer progression. Urinary protein levels served to identify bladder cancer patients. These observations suggest a role for galectin-3 as a biomarker for bladder cancer diagnostics, staging, and outcome prognosis.

[1]  Riyao Yang,et al.  Galectins in apoptosis. , 2006, Methods in enzymology.

[2]  N. Tinari,et al.  Concentrations of galectin-3 in the sera of normal controls and cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  V. Hogan,et al.  Evidence for the role of 34‐kDa galactoside‐binding lectin in transformation and metastasis , 1990, International journal of cancer.

[4]  C. Cordon-Cardo,et al.  Molecular alterations associated with bladder cancer progression. , 2007, Seminars in oncology.

[5]  A. Yoshimura,et al.  Increased expression of the LGALS3 (Galectin 3) gene in human non–small‐cell lung cancer , 2003, Genes, chromosomes & cancer.

[6]  Y. Takenaka,et al.  Galectins and urological cancer , 2004, Journal of cellular biochemistry.

[7]  S. Barondes,et al.  Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.

[8]  R. Hughes.  Secretion of the galectin family of mammalian carbohydrate-binding proteins. , 1999, Biochimica et biophysica acta.

[9]  V. Castronovo,et al.  DECREASED EXPRESSION OF GALECTIN‐3 IS ASSOCIATED WITH PROGRESSION OF HUMAN BREAST CANCER , 1996, The Journal of pathology.

[10]  Isabelle Camby,et al.  Galectins and cancer. , 2002, Biochimica et biophysica acta.

[11]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[12]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[13]  J. Serth,et al.  Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer. , 2008, Oncology reports.

[14]  Y. Takenaka,et al.  Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. , 2005, Cancer research.

[15]  R. Hughes.  Galectins as modulators of cell adhesion. , 2001, Biochimie.

[16]  L. Baum,et al.  Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death , 1998, Journal of Molecular Medicine.

[17]  H. Erdjument-Bromage,et al.  Induction of Terminal Differentiation in Epithelial Cells Requires Polymerization of Hensin by Galectin 3 , 2000, The Journal of cell biology.

[18]  H. Idikio.  Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. , 1998, International journal of oncology.

[19]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Dawson-Saunders,et al.  Basic and Clinical Biostatistics , 1993 .

[21]  R. Finley,et al.  Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria , 2002, The Journal of Biological Chemistry.

[22]  R. Kiss,et al.  Galectin fingerprinting in tumor diagnosis. Differential expression of galectin-3 and galectin-3 binding sites, but not galectin-1, in benign vs malignant uterine smooth muscle tumors. , 1999, American journal of clinical pathology.

[23]  T. Yoshii,et al.  Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.

[24]  S. Nakahara,et al.  On the role of galectins in signal transduction. , 2006, Methods in enzymology.

[25]  V. Castronovo,et al.  Galectin-3 and cancer (Review). , 2004, International journal of oncology.

[26]  K. Mishima,et al.  Expression of galectin‐1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin‐1 inhibits the growth of 9 glioma cells , 2000, Journal of neuroscience research.

[27]  M. Kurimoto,et al.  Involvement of galectin-3 expression in colorectal cancer progression and metastasis. , 1999, International journal of oncology.

[28]  A. Raz.  On the Role of Galectin-3 in Cancer Metastasis : From the Bench to the Clinic and Back , 2008 .

[29]  R. Kiss,et al.  Anti-galectin compounds as potential anti-cancer drugs. , 2006, Current medicinal chemistry.

[30]  P. Alken,et al.  Protein Profiling of Bladder Cancer Using the 2D-PAGE and SELDI-TOF-MS Technique , 2006, Technology in cancer research & treatment.

[31]  Gabriel A. Rabinovich,et al.  Galectins as modulators of tumour progression , 2005, Nature Reviews Cancer.

[32]  Riyao Yang,et al.  Expression of galectin-3 modulates T-cell growth and apoptosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Benvenuto,et al.  Galectin‐1 and galectin‐3 expression in human bladder transitional‐cell carcinomas , 1999, International journal of cancer.

[34]  R. Lotan,et al.  Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. , 2006, Cancer research.

[35]  A. Hoeflich,et al.  Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures , 2001, Journal of Cancer Research and Clinical Oncology.

[36]  H. Inohara,et al.  Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. , 1997, Cancer Research.

[37]  M. Papotti,et al.  Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. , 2005, Human pathology.

[38]  H. Kuwano,et al.  Reduced galectin-3 expression is an indicator of unfavorable prognosis in gastric cancer. , 2006, Anticancer research.

[39]  V. Castronovo,et al.  Alteration of the cytoplasmic/nuclear expression pattern of galectin‐3 correlates with prostate carcinoma progression , 2000 .

[40]  E. Jung,et al.  Galectin‐1 expression in cancer‐associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer , 2007, International journal of cancer.